FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1942096880> ?p ?o ?g. }

• W1942096880 endingPage "181" @default.
• W1942096880 startingPage "173" @default.
• W1942096880 abstract "Patients with sickle-cell disease (SCD) receiving chronic transfusions of red blood cells are at risk of developing serious adverse effects. Iron chelation therapy (ICT) helps eliminate iron overload by binding with plasma iron to form a non-toxic conjugate that can be safely excreted from the body. Two iron chelating agents are currently available in the United States: Deferoxamine (DFO) is an injectable formulation, and deferasirox (Exjade(®) ) is an oral suspension. This study compared the frequency of hospitalizations, persistence and compliance of patients with SCD from Medicaid programmes treated with DFO vs. deferasirox.Health care claims from Medicaid Florida (1998-2007), Missouri (1993-2008) and New Jersey (1996-2008) were analysed. Patients with continuous enrolment for ≥6months prior to ICT initiation and ≥1 SCD diagnosis were included in the analysis. Patients were divided into four cohorts: patients treated with DFO (any-DFO group) and patients treated with deferasirox (any-deferasirox group); the latter was further divided into patients initiated on DFO and then switched to deferasirox (deferasirox switchers), and patients treated with deferasirox-only (deferasirox-only group). Frequency of hospitalization for crisis conditions related to SCD as well as length of stay pre- and post-ICT treatment initiation were assessed. Persistence was defined as time to drug discontinuation with ≥1 Rx gap, using Kaplan-Meier approach. Compliance was estimated using a medication possession ratio (MPR) based on the drug exposure approach. Adjusted analyses of persistence and compliance were also conducted.A total of 217 (mean age: 19·4years, 39·2 men), 275 (20·1years, 41·5% men), 105 (19·4years, 42·9% men) and 166 (20·4years, 41·6% men) patients were included in the any-DFO, any-deferasirox, deferasirox switchers and deferasirox-only groups, respectively. After ICT initiation, the any-deferasirox and deferasirox-only groups experienced a statistically significant reduction in the frequency of hospitalizations relative to pretreatment [any-deferasirox: from 0·09 to 0·06 hospitalizations per patient per month (pmpm), P=0·0105; deferasirox-only: from 0·11 to 0·07 hospitalizations pmpm, P=0·0188], whereas it remained stable in the any-DFO group at 0·08 hospitalizations pmpm (P=0·9483). The Kaplan-Meier rates of medication persistence assessed at 6 and 12months of follow-up were significantly lower for DFO patients (6 months: 0·34, 12months: 0·21) as compared to all deferasirox (0·51, 0·29, P=0·0002), deferasirox switchers (0·56, 0·37, P=0·0002) and deferasirox-only (0·47, 0·24, P=0·0176) patients. Similarly, compliance to treatment was significantly lower for patients treated with DFO (mean MPR: 0·64) compared with any-deferasirox (0·78, P<0·0001), deferasirox switchers (0·75, P=0·0002) and deferasirox-only (0·80, P<0·0001) patients. Adjusted analyses of persistence and compliance yielded similar results.Based on a Medicaid population, patients treated with deferasirox were more compliant and persistent with their treatment than those treated with DFO. Frequency of hospitalizations was significantly reduced after treatment initiation for the any-deferasirox and deferasirox-only groups. Prospective studies controlling for potential clinical and treatment pattern differences between deferasirox and DFO patients are needed to assess whether the decreased hospitalizations after initiation of deferasirox are related to better treatment compliance." @default.
• W1942096880 created "2016-06-24" @default.
• W1942096880 creator A5007679884 @default.
• W1942096880 creator A5019925558 @default.
• W1942096880 creator A5025560506 @default.
• W1942096880 creator A5043332548 @default.
• W1942096880 creator A5063896009 @default.
• W1942096880 creator A5070024088 @default.
• W1942096880 date "2011-05-18" @default.
• W1942096880 modified "2023-09-26" @default.
• W1942096880 title "Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease" @default.
• W1942096880 cites W1514932744 @default.
• W1942096880 cites W1601979602 @default.
• W1942096880 cites W1973288600 @default.
• W1942096880 cites W1976258742 @default.
• W1942096880 cites W1997119525 @default.
• W1942096880 cites W2037319363 @default.
• W1942096880 cites W2037584418 @default.
• W1942096880 cites W2043084465 @default.
• W1942096880 cites W2045722771 @default.
• W1942096880 cites W2050776171 @default.
• W1942096880 cites W2069553612 @default.
• W1942096880 cites W2074897240 @default.
• W1942096880 cites W2076636544 @default.
• W1942096880 cites W2087503863 @default.
• W1942096880 cites W2090421100 @default.
• W1942096880 cites W2091974000 @default.
• W1942096880 cites W2100527638 @default.
• W1942096880 cites W2109156347 @default.
• W1942096880 cites W2118832313 @default.
• W1942096880 cites W2119692077 @default.
• W1942096880 cites W2128335522 @default.
• W1942096880 cites W2244278841 @default.
• W1942096880 cites W2550586375 @default.
• W1942096880 cites W2553599327 @default.
• W1942096880 cites W2555619027 @default.
• W1942096880 cites W2558611250 @default.
• W1942096880 cites W66151125 @default.
• W1942096880 doi "https://doi.org/10.1111/j.1365-2710.2011.01276.x" @default.
• W1942096880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21592159" @default.
• W1942096880 hasPublicationYear "2011" @default.
• W1942096880 type Work @default.
• W1942096880 sameAs 1942096880 @default.
• W1942096880 citedByCount "26" @default.
• W1942096880 countsByYear W19420968802012 @default.
• W1942096880 countsByYear W19420968802013 @default.
• W1942096880 countsByYear W19420968802014 @default.
• W1942096880 countsByYear W19420968802015 @default.
• W1942096880 countsByYear W19420968802016 @default.
• W1942096880 countsByYear W19420968802017 @default.
• W1942096880 countsByYear W19420968802018 @default.
• W1942096880 countsByYear W19420968802019 @default.
• W1942096880 countsByYear W19420968802020 @default.
• W1942096880 countsByYear W19420968802021 @default.
• W1942096880 countsByYear W19420968802022 @default.
• W1942096880 countsByYear W19420968802023 @default.
• W1942096880 crossrefType "journal-article" @default.
• W1942096880 hasAuthorship W1942096880A5007679884 @default.
• W1942096880 hasAuthorship W1942096880A5019925558 @default.
• W1942096880 hasAuthorship W1942096880A5025560506 @default.
• W1942096880 hasAuthorship W1942096880A5043332548 @default.
• W1942096880 hasAuthorship W1942096880A5063896009 @default.
• W1942096880 hasAuthorship W1942096880A5070024088 @default.
• W1942096880 hasBestOaLocation W19420968801 @default.
• W1942096880 hasConcept C126322002 @default.
• W1942096880 hasConcept C127413603 @default.
• W1942096880 hasConcept C160735492 @default.
• W1942096880 hasConcept C162324750 @default.
• W1942096880 hasConcept C187212893 @default.
• W1942096880 hasConcept C187320778 @default.
• W1942096880 hasConcept C197934379 @default.
• W1942096880 hasConcept C2776534028 @default.
• W1942096880 hasConcept C2776672577 @default.
• W1942096880 hasConcept C2777799968 @default.
• W1942096880 hasConcept C2778715236 @default.
• W1942096880 hasConcept C2781009140 @default.
• W1942096880 hasConcept C2781053155 @default.
• W1942096880 hasConcept C50522688 @default.
• W1942096880 hasConcept C71924100 @default.
• W1942096880 hasConceptScore W1942096880C126322002 @default.
• W1942096880 hasConceptScore W1942096880C127413603 @default.
• W1942096880 hasConceptScore W1942096880C160735492 @default.
• W1942096880 hasConceptScore W1942096880C162324750 @default.
• W1942096880 hasConceptScore W1942096880C187212893 @default.
• W1942096880 hasConceptScore W1942096880C187320778 @default.
• W1942096880 hasConceptScore W1942096880C197934379 @default.
• W1942096880 hasConceptScore W1942096880C2776534028 @default.
• W1942096880 hasConceptScore W1942096880C2776672577 @default.
• W1942096880 hasConceptScore W1942096880C2777799968 @default.
• W1942096880 hasConceptScore W1942096880C2778715236 @default.
• W1942096880 hasConceptScore W1942096880C2781009140 @default.
• W1942096880 hasConceptScore W1942096880C2781053155 @default.
• W1942096880 hasConceptScore W1942096880C50522688 @default.
• W1942096880 hasConceptScore W1942096880C71924100 @default.
• W1942096880 hasIssue "2" @default.
• W1942096880 hasLocation W19420968801 @default.
• W1942096880 hasLocation W19420968802 @default.
• W1942096880 hasOpenAccess W1942096880 @default.

• next